Deals this week: AB Sciex, Olympus America, Prosolia

7 April 2016 (Last Updated April 7th, 2016 18:30)

AB Sciex has entered an agreement with QPS Holdings to develop Hybrid LBA-LCMS, a workflow for regular biologics quantification.

University of South Florida

AB Sciex has entered an agreement with QPS Holdings to develop Hybrid LBA-LCMS, a workflow for regular biologics quantification.

The agreement enables AB Sciex and QPS Holdings to further develop bioanalysis of biologics.

According to the contract, QPS Holdings will use Sciex's BioBA solution for bioanalysis of biologics. The BioBA solution includes ready-to-use sample preparation kits, automated liquid sample handler, LC component with high-resolution, and a sensitive QTRAP MS system with software for performing bio-analytical studies.

Olympus America has reached a distribution agreement with AMICO to include an OR design element to its Olympus systems integration business, combining a best-in-class imaging system, comprehensive integration offering and infrastructure products.

The agreement allows Olympus to develop its product line.

Prosolia has signed a research agreement with University of Florida, Department of Chemistry and Pathology to develop translational science application for health and disease.

"Human Longevity has raised more than $220m through a series B financing round."

The agreement enables Prosolia and University of Florida to develop and apply Prosolia's flowprobe technology for clinical research.

Human Longevity has raised more than $220m through a series B financing round. The finance was provided by Illumina, Celgene Corporation, GE Ventures, in participation with series A investors, representing the investors based in the UK, Malaysia, Mexico, Australia, Kuwait, Hong Kong, China and US.

The company plans to use the proceeds to fund the development and expansion of its products, which include Health Nucleus, ongoing development of its knowledgebase, and also comprehensive cancer programme, as well as other sequencing programmes.

HCi Viocare has announced the public offering its shares to raise gross proceeds of approximately $34.16m.

The company intends to use proceeds for marketing its patent pending 'smart insole', development of its other smart medical solutions, for general operating capital, as well as expansion of its prosthetics and orthotics and diabetic foot clinics.


Image:Prosolia has signed a research agreement with University of Florida, Department of Chemistry and Pathology to develop translational science application: Photo: courtesy of Amy Kellogg.